Kura Oncology, Inc. (KURA)
9.61
-0.25
(-2.54%)
USD |
NASDAQ |
Oct 23, 16:00
9.61
0.00 (0.00%)
After-Hours: 20:00
Kura Oncology Enterprise Value : 360.28M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 360.28M |
| October 22, 2026 | 382.52M |
| October 21, 2026 | 384.30M |
| October 20, 2026 | 393.19M |
| October 19, 2026 | 338.04M |
| October 16, 2026 | 313.13M |
| October 15, 2026 | 368.28M |
| October 14, 2026 | 360.28M |
| October 13, 2026 | 379.85M |
| October 12, 2026 | 430.11M |
| October 09, 2026 | 448.34M |
| October 08, 2026 | 441.23M |
| October 07, 2026 | 454.57M |
| October 06, 2026 | 442.12M |
| October 05, 2026 | 450.12M |
| October 02, 2026 | 452.79M |
| October 01, 2026 | 452.79M |
| September 30, 2026 | 458.13M |
| September 29, 2026 | 466.58M |
| September 28, 2026 | 449.23M |
| September 25, 2026 | 462.58M |
| September 24, 2026 | 471.47M |
| September 23, 2026 | 487.48M |
| September 22, 2026 | 548.86M |
| September 21, 2026 | 537.30M |
| Date | Value |
|---|---|
| September 18, 2026 | 548.86M |
| September 17, 2026 | 547.97M |
| September 16, 2026 | 501.71M |
| September 15, 2026 | 510.61M |
| September 14, 2026 | 533.74M |
| September 11, 2026 | 518.62M |
| September 10, 2026 | 534.63M |
| September 09, 2026 | 580.88M |
| September 08, 2026 | 619.13M |
| September 04, 2026 | 684.07M |
| September 03, 2026 | 675.18M |
| September 02, 2026 | 671.62M |
| September 01, 2026 | 652.05M |
| August 31, 2026 | 630.70M |
| August 28, 2026 | 631.59M |
| August 27, 2026 | 677.84M |
| August 26, 2026 | 667.17M |
| August 25, 2026 | 714.31M |
| August 24, 2026 | 608.46M |
| August 21, 2026 | 563.09M |
| August 20, 2026 | 547.08M |
| August 19, 2026 | 620.02M |
| August 18, 2026 | 602.23M |
| August 17, 2026 | 508.83M |
| August 14, 2026 | 471.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Inovio Pharmaceuticals, Inc. | 45.20M |
| Fortress Biotech, Inc. | -37.02M |
| Spero Therapeutics, Inc. | 15.81M |
| Gossamer Bio, Inc. | 41.73M |
| ACADIA Pharmaceuticals, Inc. | 2.514B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -68.33M |
| Revenue (Quarterly) | 20.87M |
| Total Expenses (Quarterly) | 89.20M |
| EPS Diluted (Quarterly) | -0.769 |
| Gross Profit Margin (Quarterly) | 97.07% |
| Profit Margin (Quarterly) | -327.3% |
| Earnings Yield | -34.99% |
| Normalized Earnings Yield | -34.99 |